Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent.
A new layered organic-inorganic nanocomposite material with an anti-parkinsonian active compound, L-3-(3,4-dihydroxyphenyl) alanine (levodopa), intercalated into the inorganic interlayers of a Zn/Al-layered double hydroxide (LDH) was synthesized using a direct coprecipitation method. The resulting n...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English English |
| Published: |
Dove Medical Press
2013
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/29991/ http://psasir.upm.edu.my/id/eprint/29991/1/Development%20of%20a%20controlled.pdf |
| _version_ | 1848846552250974208 |
|---|---|
| author | Kura, Aminu Umar Hussein Al Ali, Samer Hasan Hussein, Mohd. Zobir Fakurazi, Sharida Arulselvan, Palanisamy |
| author_facet | Kura, Aminu Umar Hussein Al Ali, Samer Hasan Hussein, Mohd. Zobir Fakurazi, Sharida Arulselvan, Palanisamy |
| author_sort | Kura, Aminu Umar |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | A new layered organic-inorganic nanocomposite material with an anti-parkinsonian active compound, L-3-(3,4-dihydroxyphenyl) alanine (levodopa), intercalated into the inorganic interlayers of a Zn/Al-layered double hydroxide (LDH) was synthesized using a direct coprecipitation method. The resulting nanocomposite was composed of the organic moiety, levodopa, sandwiched between Zn/Al-LDH inorganic interlayers. The basal spacing of the resulting nano-composite was 10.9 Å. The estimated loading of levodopa in the nanocomposite was approximately 16% (w/w). A Fourier transform infrared study showed that the absorption bands of the nanocomposite were characteristic of both levodopa and Zn/Al-LDH, which further confirmed intercalation, and that the intercalated organic moiety in the nanocomposite was more thermally stable than free levodopa. The resulting nanocomposite showed sustained-release properties, so can be used in a controlled-release formulation. Cytotoxicity analysis using an MTT assay also showed increased cell viability of 3T3 cells exposed to the newly synthesized nanocomposite compared with those exposed to pure levodopa after 72 hours of exposure. |
| first_indexed | 2025-11-15T09:04:31Z |
| format | Article |
| id | upm-29991 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English English |
| last_indexed | 2025-11-15T09:04:31Z |
| publishDate | 2013 |
| publisher | Dove Medical Press |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-299912015-09-18T01:31:39Z http://psasir.upm.edu.my/id/eprint/29991/ Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. Kura, Aminu Umar Hussein Al Ali, Samer Hasan Hussein, Mohd. Zobir Fakurazi, Sharida Arulselvan, Palanisamy A new layered organic-inorganic nanocomposite material with an anti-parkinsonian active compound, L-3-(3,4-dihydroxyphenyl) alanine (levodopa), intercalated into the inorganic interlayers of a Zn/Al-layered double hydroxide (LDH) was synthesized using a direct coprecipitation method. The resulting nanocomposite was composed of the organic moiety, levodopa, sandwiched between Zn/Al-LDH inorganic interlayers. The basal spacing of the resulting nano-composite was 10.9 Å. The estimated loading of levodopa in the nanocomposite was approximately 16% (w/w). A Fourier transform infrared study showed that the absorption bands of the nanocomposite were characteristic of both levodopa and Zn/Al-LDH, which further confirmed intercalation, and that the intercalated organic moiety in the nanocomposite was more thermally stable than free levodopa. The resulting nanocomposite showed sustained-release properties, so can be used in a controlled-release formulation. Cytotoxicity analysis using an MTT assay also showed increased cell viability of 3T3 cells exposed to the newly synthesized nanocomposite compared with those exposed to pure levodopa after 72 hours of exposure. Dove Medical Press 2013-03 Article PeerReviewed application/pdf en http://psasir.upm.edu.my/id/eprint/29991/1/Development%20of%20a%20controlled.pdf Kura, Aminu Umar and Hussein Al Ali, Samer Hasan and Hussein, Mohd. Zobir and Fakurazi, Sharida and Arulselvan, Palanisamy (2013) Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. International Journal of Nanomedicine, 8 (1). pp. 1103-1110. ISSN 1176-9114; ESSN: 1178-2013 http://www.dovepress.com/international-journal-of-nanomedicine-i750-j5 10.2147/IJN.S39740 English |
| spellingShingle | Kura, Aminu Umar Hussein Al Ali, Samer Hasan Hussein, Mohd. Zobir Fakurazi, Sharida Arulselvan, Palanisamy Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. |
| title | Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. |
| title_full | Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. |
| title_fullStr | Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. |
| title_full_unstemmed | Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. |
| title_short | Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. |
| title_sort | development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. |
| url | http://psasir.upm.edu.my/id/eprint/29991/ http://psasir.upm.edu.my/id/eprint/29991/ http://psasir.upm.edu.my/id/eprint/29991/ http://psasir.upm.edu.my/id/eprint/29991/1/Development%20of%20a%20controlled.pdf |